OTS - ONE DRUG FOR ONE BUG: DEBIOPHARM TO DISCUSS THE POTENTIAL OF PATHOGEN-SPECIFIC ANTIBIOTICS AT THE 2022 WORLD AMR CONGRESS (part 1)
2022. September 08. 09:23
Lausanne, Switzerland, 8 September, 2022 (APA/OTS) - International
health authorities, such as the WHO and the CDC are warning of the
emerging danger of bacterial infections resistant to current
antibiotics - The 2022 World Anti-Microbial Resistance (AMR)
Congress in the greater Washington D.C. area is serving as a forum
to openly address the threat of AMR - Debiopharm will join the
action-focused discussions around this silent pandemic in 3 panel
discussions, presenting their microbiome-sparing FabI inhibitor
class as a future tool to fight AMR
Debiopharm, (www.debiopharm.com) a privately-owned,
Swiss-based, biopharmaceutical company committed to the development
of novel class antibiotics, today revealed its involvement in three
panel discussions at the World AMR Congress, taking place in Fort
Washington, Maryland, from September 7th - 8th. This conference
offers pharmaceutical companies, government, and policy
stakeholders from all around the world the opportunity to meet,
discuss and formulate initiatives to effectively tackle the
emerging threat of antimicrobial resistance. Debiopharm will
present developments on its FabI inhibitor antibiotic class
including afabicin (Debio 1450), Debio 1453 and Debio 1454S, all of
which have microbiome-sparing potential, a promising characteristic
for AMR prevention.
AMR is a leading cause of death and disability and represents a
major threat to human health. Among the 1.27 million deaths [1]
that occur globally due to antibiotic-resistant infections each
year, more than 35,000 [2] occur in the United States and over 33,
[3] occur in Europe. The economic burden of AMR is also significant
[4] in direct health care and lost productivity costs are
attributable to antibiotic-resistant bacteria like Staphylococcus
spp.
The WHO and the CDC have identified such pathogens posing a
threat to public health and Debiopharm, one of the few private
companies still engaged in the development of novel antibiotics,
has directed its efforts toward targeting them. The World AMR
summit offers a great opportunity to governments, funds,
associations, and passionate companies like Debiopharm to join
forces against one of the top global public threats facing humanity.
"We're proud to unveil more on the role our novel class
antibiotic, the FabI inhibitors, amongst key international
stakeholders at the World AMR. We're hoping that our collaboration
with specialized organizations and lawmakers will trigger the much
needed changes in the way we think about the unmet need for
antibiotics as well as provide hope to people and health
practitioners dealing with these seemingly insurmountable
infections" stated Mohammed Benghezal, Global Project Lead in
Anti-infectives, Debiopharm.
"Pathogen-specific antibiotic effect without harming the "good"
gut bacteria: it is the best of both worlds! As we research their
efficacy and safety profile, this class of antibiotics could be
like no other," expressed Ricardo Chaves, Executive Medical
Director, Debiopharm. "Now is the time to encourage the development
of new antibiotic classes by establishing new business models that
will assure future patients access to effective treatments that
will knock out highly resistant bacterial infections and at the
same time prevent AMR development."
World AMR 2022 Congress agenda Speakers
Session Details
================ =======================
======================================
Session 1 - Disease Prevention & Ricardo Chaves, Executive Medical
Sept.7th, Control Summit – Director, Debiopharm + other
invited
Keynote panel Funding & Commercial speakers
discussion, Landscape
09:40 – 10:20
EST
---------------- -----------------------
--------------------------------------
Session 2 - Antibiotic Development Ricardo Chaves, Executive Medical
Sept.7th, – Panel Discussion / Director, Debiopharm; Vance Fowler,
11:40-12:10 EST Pathogen-specific Professor of Medicine, c and
antibiotic therapy: A Microbiology, Duke University, North
new paradigm to face Carolina; James Anderson, Executive
AMR? Director Global Health, IFPMA
---------------- -----------------------
--------------------------------------
Session 3 - Innovation Showcase - Riccardo Nisato, Licensing and
Grant
Sept.8th, Microbiome / One Drug Associate Manager, Debiopharm;
11:40-12:00 EST for One Bug: FabI Novel Mohammed Benghezal, Global Project
Class Antibiotics for Lead in Anti-infectives, Debiopharm
Microbiome Sparing and
AMR Prevention
---------------- -----------------------
--------------------------------------